DATING - CANCER DIAGNOSIS
Personalised medicine focuses on tailoring the treatment strategy to the individual patient.
It is therefore necessary to analyse the specific characteristics and features of the tumour in order to determine the best possible therapy.
In addition, some of this information can also be used for early tumour detection or to perform tumour screening in asymptomatic individuals.
Datar Cancer Genetics has set itself the task of offering solutions, especially in advanced stages (e.g. breast cancer, prostate cancer) or in solid tumours that are difficult to treat.
At the same time, we recognise that early detection of cancer is much more likely to lead to successful treatment, for example in colon cancer or ovarian carcinoma.
There is a wealth of information available in the blood, the analysis of which, combined with advanced artificial intelligence, helps to optimise therapy.
Based on clinical studies in recent years, Datar Cancer Genetics has been able to develop evidence-based testing procedures in both therapy management and cancer screening.
In total, more than 40,000 patients have been enrolled in our studies to date, making a significant contribution to cancer diagnosis and therapy.
Minimally invasive
Quick results
Early detection of cancer/tumour
Identification of a relavant target for individual therapy
Monitoring tumour development
trucheck
Early detection of cancer
Trucheck™ is a new blood paradigm for the detection of multiple types of cancer.
The following options are available:
– Trucheck™ intelli (up to 70 types of solid tumors)
– Trucheck™ FemmeSafe (breast, ovarian, uterine, cervical)
trublood
Supplement to biopsy
Trublood is a minimally invasive diagnostic test that can clearly identify cancer in symptomatic patients. Trublood provides diagnostic information similar to that offered by tissue biopsy when it is inconclusive or not feasible. Based on the test results, therapy can be adjusted.
exacta
The most comprehensive tumour examination
exacta is a comprehensive analysis of the molecular-genetic characteristics of solid tumours, based on the results of several clinical studies.
Especially for rare solid tumours for which no guidelines are available, in advanced disease or for difficult-to-treat tumours, Exacta is an advantage.
Exacta analyses millions of data at the molecular level to identify all relevant targets for individualised therapy.
celldx
Deep genomic analysis of solid tumours
Celldx is a tissue-based comprehensive molecular profiling of solid tumours to tailor treatment options.
Results are usually available within eight working days and, in addition to genetic analysis, provide information on the usefulness of immune checkpoint inhibitors.
cancertrack
Blood-based follow-up for all solid organic tumours
Cancertrack is a blood-based assay that detects cancer-related biomarkers with extremely high accuracy, specificity and reliability.
Cancertrack enables continuous cancer monitoring to detect recurrences or changes in tumour characteristics at an early stage.
chemo-scale
Minimally invasive in-vitro chemotherapy susceptibility testing
Cancer is an extremely heterogeneous disease.
Chemotherapies do not work the same for every patient.
Chemo-scale uses a blood sample to study the effectiveness of chemotherapies in an individual patient.
The likelihood of successful therapy can be significantly increased in certain cases, while treatment failure can be largely prevented.
